Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

Sunshine Biopharma (SBFM) Long-Term Debt Repayments: 2015-2022

Historic Long-Term Debt Repayments for Sunshine Biopharma (SBFM) over the last 2 years, with Mar 2022 value amounting to $1.9 million.

  • Sunshine Biopharma's Long-Term Debt Repayments rose 3858.33% to $1.9 million in Q1 2022 from the same period last year, while for Mar 2022 it was $2.3 million, marking a year-over-year increase of 1021.06%. This contributed to the annual value of $1.9 million for FY2022, which is 299.73% up from last year.
  • According to the latest figures from Q1 2022, Sunshine Biopharma's Long-Term Debt Repayments is $1.9 million, which was up 7,929.07% from $23,664 recorded in Q4 2021.
  • In the past 5 years, Sunshine Biopharma's Long-Term Debt Repayments ranged from a high of $1.9 million in Q1 2022 and a low of -$767 during Q2 2019.
  • Over the past 3 years, Sunshine Biopharma's median Long-Term Debt Repayments value was $115,454 (recorded in 2020), while the average stood at $413,654.
  • As far as peak fluctuations go, Sunshine Biopharma's Long-Term Debt Repayments slumped by 105.02% in 2019, and later soared by 3,858.33% in 2022.
  • Sunshine Biopharma's Long-Term Debt Repayments (Quarterly) stood at $48,000 in 2018, then slumped by 105.02% to -$767 in 2019, then reached $106,600 in 2020, then tumbled by 77.80% to $23,664 in 2021, then skyrocketed by 3,858.33% to $1.9 million in 2022.
  • Its last three reported values are $1.9 million in Q1 2022, $23,664 for Q4 2021, and $124,309 during Q3 2021.